This article was originally published in The Gray Sheet
Is in discussions with several firms regarding the potential sale of its external temporary pacemaker business. A 510(k) for the company's external pacemaker was submitted in August 1992; FDA subsequently requested additional information, which has been submitted, according to the firm. Proceeds would be used to fund the Minneapolis firm's implantable defibrillator and laser catheter projects, according to the company's third quarter (ended April 30) report. Clinical trials for the laser catheter are under way; preclinical tests with the defibrillator are continuing ("The Gray Sheet" July 20, 1992, p. 12)....
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.